Pamela Soliman

Associate Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Supplementary Figure S3 Clinical courses of MRD+ cases and tumor expression profiles in MRD lesions. (A) The expression of potential therapeutic targets and genes of interest in the tumor region of sample 3A, the MRD sample from Pt-10. (B) The clinical course of the other three MRD+ cases, as represented by dynamic changes of serum CA-125 level, along with H&E staining, pathology annotations of tumor and non-tumor regions, as well as the expression of potential therapeutic targets and genes of interest in the MRD samples.

Year:

2025

Purpose: Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational value of MRD detection by second-look laparoscopy (SLL) and ctDNA at the completion of first-line therapy. Experimental Design: Patients with high-grade epithelial ovarian cancer who had a complete clinical response to first-line therapy and underwent SLL and plasma collection for ctDNA were included. Progression-free survival (PFS) and overall survival (OS) were estimated based on MRD and clinicopathologic status. Spatial transcriptomics (GeoMx and Visium) and proteomics (CODEX) profiling were performed on serial samples from select patients. Results: Forty of 95 (42.1%) patients had surgically detected MRD, which was associated with worse PFS (median PFS 7.4 vs. 23.8 months; P P P = 0.013) in multivariable analysis. Among 44 patients who underwent SLL and had ctDNA testing, 34% (15/44) were ctDNA-positive, which was associated with worse PFS (6.4 vs. 28.1 months; P P = 0.008). We demonstrated the feasibility of spatial multiomics in studying MRD and their ability to provide hypothesis-generating observations, implicating the upregulation of the hypoxia signaling pathway, expression of multiple druggable targets ( CDK6 , GLS , MSLN , ERBB2 ), and immune exclusion in MRD lesions. Conclusions: Approximately half of patients in clinical remission after first-line therapy have assessable MRD, which can inform prognosis, therapeutic target discovery, and clinical trials.

Year:

2025

Supplementary Figure S4 Immune exclusion in the SLL sample 6B revealed by orthogonal spatial profiling. (A) CODEX profiling revealed two representative regions in the MRD sample (6B) of Pt-67. Region 1 located in the tumor margin where tumor cells interfaced with abundant CD8 T cells that demonstrated an exhausted state. This region was also enriched for interferon-stimulating signals. In contrast, region 2 represented tumor interior where very few CD8 T cells were observed. (B) Visium spatial profiling of the same sample as (A). CD8 T cell signals were detected in the tumor margin, which highly overlapped with the signals of immune checkpoint and interferon-stimulated genes.

Year:

2025

Supplementary Figure S2 Transcriptomic level comparisons of the tumor compartment between MRD and IDS samples using GeoMx data. (A) Volcano plot showing DEGs between the tumor compartment of MRD and IDS samples, with genes related to hypoxia signaling highlighted. (B) GSEA showing enriched pathways in the tumor compartment of MRD samples.

Year:

2025

Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.

Year:

2025

PURPOSE Hypomagnesemia is a common side effect of platinum-based chemotherapy and predicts poor overall survival in some cancers. Standard magnesium replacement strategies are often inadequate for maintaining magnesium levels. We hypothesized that a daily dietary magnesium replacement approach through magnesium-rich foods would help maintain adequate magnesium levels during platinum-based treatment. MATERIALS AND METHODS We conducted a prospective feasibility study of magnesium-rich diets in patients 18 years and older with previously untreated ovarian cancer scheduled to receive carboplatin-containing chemotherapy of at least six consecutive cycles. Education about magnesium-rich diets was provided at enrollment and then weekly during chemotherapy. Feasibility was defined as ≥60% completion of dietary recalls and ≥280 mg average daily dietary magnesium intake across all patients. RESULTS Twenty-one of 26 patients enrolled completed at least five chemotherapy cycles and were included in the analysis. Adherence to the study diet was 76%. Daily dietary magnesium intake was 100.5 mg at baseline and increased throughout each cycle: 6% of patients at baseline, 24% after the first cycle, and 67% after the fifth cycle reached ≥280-mg/day magnesium intake. Seven (33%) of 21 had at least one incident of hypomagnesemia. Patients who were adherent had significantly lower incidence of hypomagnesemia (19% v 80%, P = .03) and less need for intravenous magnesium (6% v 60%, P = .03) than those who were nonadherent. CONCLUSION The study achieved primary feasibility objectives of retention and adherence to the study intervention. Weekly education about magnesium-rich diets was effective in increasing dietary magnesium intake. Adequate dietary magnesium appeared to be protective against hypomagnesemia.

Year:

2024

Year:

2024

Purpose: We aimed to describe RAS mutations in gynecologic cancers as they relate to clinicopathologic and genomic features, survival, and therapeutic implications. Experimental Design: Gynecologic cancers with available somatic molecular profiling data at our institution between February 2010 and August 2022 were included and grouped by RAS mutation status. Overall survival was estimated by the Kaplan–Meier method, and multivariable analysis was performed using the Cox proportional hazard model. Results: Of 3,328 gynecologic cancers, 523 (15.7%) showed any RAS mutation. Patients with RAS-mutated tumors were younger (57 vs. 60 years nonmutated), had a higher prevalence of endometriosis (27.3% vs. 16.9%), and lower grades (grade 1/2, 43.2% vs. 8.1%, all P KRAS mutation was in mesonephric-like endometrial (100%, n = 9/9), mesonephric-like ovarian (83.3%, n = 5/6), mucinous ovarian (60.4%), and low-grade serous ovarian (44.4%) cancers. After adjustment for age, cancer type, and grade, RAS mutation was associated with worse overall survival [hazard ratio (HR) = 1.3; P = 0.001]. Specific mutations were in KRAS (13.5%), NRAS (2.0%), and HRAS (0.51%), most commonly KRAS G12D (28.4%) and G12V (26.1%). Common co-mutations were PIK3CA (30.9%), PTEN (28.8%), ARID1A (28.0%), and TP53 (27.9%), of which 64.7% were actionable. RAS + MAPK pathway-targeted therapies were administered to 62 patients with RAS-mutated cancers. While overall survival was significantly higher with therapy [8.4 years [(95% confidence interval (CI), 5.5–12.0) vs. 5.5 years (95% CI, 4.6–6.6); HR = 0.67; P = 0.031], this effect did not persist in multivariable analysis. Conclusions: RAS mutations in gynecologic cancers have a distinct histopathologic distribution and may impact overall survival. PIK3CA , PTEN , and ARID1A are potentially actionable co-alterations. RAS pathway-targeted therapy should be considered.

Year:

2024

Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.

Year:

2024

Clinical efficacy of RAS + MAPK pathway inhibitors in patients with RAS-mutated gynecologic cancers: (a) histologic breakdown and (b) multivariable analysis for overall survival in type 1, type 2, and low-grade serous ovarian cancers.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (36)

Richard Yang

Assistant Professor, Molecular Genetic Pathology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Rossana Lazcano

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christina Lynn Roland

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jianjun Gao

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Larissa A. Meyer

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Roni Wilke

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yisheng LI

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anil Sood

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sanghoon Lee

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Amir Jazaeri

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shreyaskumar Patel

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Gershenson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anthony P. Conley

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jeffrey How

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Meroe Morse

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Euscher

Professor

MD Anderson Cancer Center

UNITED STATES
View details

Yibo Dai

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Shannon Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gwyn Richardson

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J Andrew Livingston

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Manoj Chelvanambi

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gabriel Lopez

Associate Professor, Medical Director Integrative Medicine Center

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Cara Haymaker

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

R. Tyler Hillman

Associate Professor

UC San Diego Health System

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Ying Yuan

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Kai Wucherpfennig

Professor and Department Chair

Dana-Farber Cancer Institute

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Wei-Lien Wang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Linghua Wang

Executive Director & Head

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David Boruta

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Chia-Chin Wu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details